ELLICOTT CITY, Md. — The Alliance of Sleep Apnea Partners (ASAP), the nation's leading patient advocacy organization for people living with obstructive sleep apnea (OSA), responds to Apnimed's announcement today of positive Phase 3 clinical trial results for AD109, an investigational once-daily oral medication for OSA.

​

"Today's announcement represents a potentially transformative moment for the millions of Americans living with sleep apnea," said Dr. Monica Mallampalli, President and CEO of the Alliance of Sleep Apnea Partners. "For decades, patients have faced limited treatment options that many find difficult to tolerate or incorporate into their daily lives. The possibility of an effective oral medication that targets the root cause of OSA could dramatically improve how this serious condition is managed."

​

The Phase 3 SynAIRgy clinical trial results showed that AD109 achieved a mean reduction in patients’ apnea-hypopnea index (AHI) of 55.6% from baseline. AHI is the average number of times a patient stops breathing (apnea) or has abnormally shallow breathing (hypopnea) in an hour. Slightly more than half of trial participants experienced a reduction in OSA disease severity category. Notably, 22.3% of participants reached complete disease control, defined as fewer than five breathing events per hour.

​

"While we are encouraged by these results, we also recognize the importance of continued research and development of multiple treatment options," added Mallampalli. "Sleep apnea is a complex condition that affects people differently. Our community needs a range of effective treatments to address the full spectrum of patient needs and preferences."

​

ASAP supports the development  of innovative treatment options, whether used alone or in combination with existing therapies, allowing people living with OSA to manage their symptoms effectively and have better quality of life. 

​

ASAP plans to work closely with healthcare providers, insurers, and policymakers to ensure that, if approved, this new treatment option becomes accessible to all patients who could benefit.

 

About Obstructive Sleep Apnea

Obstructive sleep apnea is a serious chronic health condition characterized by repeated collapse of the upper airway during sleep, leading to interrupted breathing and oxygen deprivation. OSA affects people of all ages, genders, ethnicities, and body types, though it often goes undiagnosed. Left untreated, OSA can increase the risk of heart disease, stroke, type 2 diabetes, and other serious health complications.

​

About the Alliance of Sleep Apnea Partners

The Alliance of Sleep Apnea Partners (ASAP) is a U.S. based patient-oriented non-profit organization dedicated to improving the lives of people with sleep apnea through education, advocacy and support. Founded in 2018, ASAP is committed to promoting screening, diagnosis, treatment, and management of sleep apnea on behalf of the patient community to advance the lifelong well-being of sleep apnea patients.

 

Contact:
Monica P. Mallampalli, PhD

Alliance of Sleep Apnea Partners
info@apneapartners.org

1-855-545-1717